We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cannabis as a Complementary Treatment in Multiple Sclerosis (CAN-SEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05092191
Recruitment Status : Recruiting
First Posted : October 25, 2021
Last Update Posted : December 1, 2022
Sponsor:
Collaborators:
Canadian Institutes of Health Research (CIHR)
Multiple Sclerosis Society of Canada
Information provided by (Responsible Party):
Centre hospitalier de l'Université de Montréal (CHUM)

Brief Summary:

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) afflicting over 77,000 Canadians. Unfortunately, the therapeutic arsenal to relieve MS symptoms is limited. It is therefore essential to develop better approaches to treat the symptoms of MS. The use of cannabis for recreational purposes is now legal in Canada. However, for many years, people with Multiple Sclerosis (PwMS) have used cannabis either to relax, to reduce pain and spasticity, or to improve sleep and daily functioning. Currently, there is little scientifically established evidence that cannabis works on these symptoms in people with MS. It is therefore important to carry out studies to better understand the efficacy Δ-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) on MS symptoms . THC is known for its analgesic, neuroprotective and anti-inflammatory properties and CBD seems to have positive effects on anxiety and cognitive abilities (memory, concentration).

For this study, investigators hypothesize that administering different doses of THC alone, CBD alone, and THC and CBD combined will result in a significant beneficial effect on spasticity relief compared to placebo.


Condition or disease Intervention/treatment Phase
Multiple Sclerosis Drug: Cannabis oil vs placebo Phase 2

Detailed Description:

The aim of this study is to document,

  1. The efficacy of THC and CBD, alone and in combination, as add-on therapies to the current standard treatments for relief of spasticity and other symptoms in PwMS (muscle spasms and stiffness);
  2. Assess the tolerability profile of THC and CBD, alone and in combination, when used in PwMS;
  3. Identify the mechanisms underlying such therapeutic and adverse effects of different types of cannabis-based medicines in PwMS,

Participants will initially receive THC 4mg/day or CBD 40mg/day or THC/CBD combination (THC 4mg and CBD 40mg/day), or placebo, on the first day. Dose will be increased up to 20mg (THC) and 200mg (CBD) per day, if well tolerated. Participants will receive the allocated treatment for a total of 4 weeks, followed by an additional 12 weeks of treatment for responders who will be identified as patients who had a decrease from baseline in spasticity of at least one point on the Numerical Rating Scale . THC and CBD will be taken as oil softgels in two divided doses per day. Cannabis extract and placebo will taste and look exactly the same.

To protect from all contingencies and to minimize the risk of adverse reactions, the presence of adverse events will be evaluated at each research visit, as well as through courtesy calls between visits. If any mental or physical symptoms occur that require medical attention, the PwMS will be referred as required to an attending neurologist, psychiatrist, or other specialists .

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Efficacy of Cannabinoids to the Current Standard Treatments on Symptom Relief in Persons With Multiple Sclerosis: Randomized Controlled Trial
Actual Study Start Date : November 10, 2022
Estimated Primary Completion Date : March 15, 2024
Estimated Study Completion Date : March 15, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CBD alone
  • Dosage form : Softgel
  • Dosage & frequency : 40 mg /day of CBD up to 200 mg in two doses a day
  • Duration : 4 weeks of treatment followed by 12 additional weeks of follow up.
Drug: Cannabis oil vs placebo

Eligibility, Screening and Baseline (T0):

Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .

Follow-up visits:

Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.

At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.

Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being.

Other Name: Randomized Controlled Trial

Experimental: THC alone
  • Dosage form : Softgel
  • Dosage & frequency : 4 mg /day of THC up to 20 mg in two doses a day
  • Duration : 4 weeks of treatment followed by 12 additional weeks of follow up.
Drug: Cannabis oil vs placebo

Eligibility, Screening and Baseline (T0):

Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .

Follow-up visits:

Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.

At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.

Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being.

Other Name: Randomized Controlled Trial

Experimental: THC and CBD combined
  • Dosage form : Softgel
  • Dosage & frequency : 40 mg /day of CBD up to 200 mg and 4 mg /day of THC up to 20 mg in two doses a day
  • Duration : 4 weeks of treatment followed by 12 additional weeks of follow up.
Drug: Cannabis oil vs placebo

Eligibility, Screening and Baseline (T0):

Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .

Follow-up visits:

Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.

At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.

Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being.

Other Name: Randomized Controlled Trial

Placebo Comparator: Placebo
  • Dosage form : Softgel
  • Dosage & frequency : caps of placebo twice a day
  • Duration : 4 weeks of treatment followed by 12 additional weeks of follow up.
Drug: Cannabis oil vs placebo

Eligibility, Screening and Baseline (T0):

Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .

Follow-up visits:

Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.

At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.

Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being.

Other Name: Randomized Controlled Trial




Primary Outcome Measures :
  1. Spasticity patient reported change assessment [ Time Frame: Change from Baseline Patient reported spasticity at 28 weeks and 16 weeks ]
    Patient-reported spasticity: a Numerical rating scale - 0 (No pain) to 10 (worst pain)


Other Outcome Measures:
  1. Spasticity change Clinician assessment [ Time Frame: Change from Baseline Clinician evaluation spasticity at 28 weeks and 16 weeks ]
    Spasticity: Ashworth scale -1 (normal) to 4 (rigid)

  2. Pain change assessment [ Time Frame: Change from Baseline pain at 28 weeks and 16 weeks ]
    Pain: Pain Effects-1 (Not at all) to 4 (extreme)

  3. Mobility Change assessement [ Time Frame: Change from Baseline mobility at 28 weeks and 16 weeks ]
    Mobility: Timed 25-Foot Walk test

  4. Fatigue change assessement [ Time Frame: Change from Baseline fatigue at 28 weeks and 16 weeks ]
    Fatigue: Modified Fatigue Impact Scale-0 (never) to 4 (always)

  5. Sleep change assessement [ Time Frame: Change from Baseline sleep at 28 weeks and 16 weeks ]
    Sleep: Pittsburgh Study Quality sleep Index-0 (no difficult) to 3 (severe)

  6. Drowsiness change assessement [ Time Frame: Change from Baseline Drowsiness at 28 weeks and 16 weeks ]
    Drowsiness: Epworth Sleepiness scale-0 (no chance) to 3 (High chance)

  7. Bowel /Bladder dysfunction change assessement [ Time Frame: Change from Baseline Bowel/Bladder dysfunction at 28 weeks and 16 weeks ]
    Bowel /Bladder dysfunction: Bowel/Bladder Control Scale-0 (not at all) to 4 (Daily)

  8. Sexual dysfunction change assessement [ Time Frame: Change from Baseline Sexual dysfunction at 28 weeks and 16 weeks ]
    Sexual dysfunction: Sexual Satisfaction Scale-0 (Extremely Satisfied) to 6 (Extremely Dissatisfied)

  9. Restless Legs Syndrome change assessement [ Time Frame: Change from Baseline Restless Legs Syndrome at 28 weeks and 16 weeks ]
    Restless Legs Syndrome - 4 (V.severe) to 0 (None)

  10. Mental Health disorder change assessement [ Time Frame: Change from Baseline Mental Health at 28 weeks and 16 weeks ]
    Mental Health issues: Mental Health inventory-1 (All of the time) to 6 (None of the time)

  11. Anxiety/Depression change assessement [ Time Frame: Change from Baseline Anxiety/Depression at 28 weeks and 16 weeks ]
    Anxiety/Depression: Hospital Anxiety and Depression-0 to 3 (highest level)

  12. Cannabis use disorder assesssment [ Time Frame: Cannabis use disorder : assessment at only baseline ]
    Cannabis use disorder : diagnosis

  13. Cognition change assessement [ Time Frame: Change from Baseline cognition at 28 weeks and 16 weeks ]
    Cognition tests

  14. Quality of life change assessement [ Time Frame: Change from Baseline Quality of life at 28 weeks and 16 weeks ]
    Quality of life: Health Status Questionnaire (Higher scores indicate better health)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants must meet the following criteria:

  1. Diagnosed with MS (any subtype), for at least six months, by a MS neurologist, according to the recent version of the McDonald criteria;
  2. Spasticity due to MS of at least one-month duration and not relieved with current therapy, at a level of 4 or more on the numerical rating scale (NRS);
  3. Stable dose of standard therapies for at least 30 days prior to the screening visit and willingness for these to be maintained for the duration of the study;
  4. Aged 21 years or older;
  5. Ability (in the investigator's opinion) and willingness to comply with all study requirements;
  6. Ability to speak and read French or English (grade-nine level of language required);

Exclusion Criteria:

Participants will be excluded if any of the following criteria are met:

  1. Concomitant disease with symptoms of spasticity, or that may have influenced their level;
  2. Received a botulinum toxin injection within four months prior to the screening visit or unwillingness to stop receiving botulinum toxin injections for the duration of the study;
  3. Use of cannabis or cannabinoid-based medications within 7 days of study entry and unwillingness to abstain for the duration of the study;
  4. History of schizophrenia, other psychotic illness or other significant psychiatric disorder other than anxiety or depression associated with their underlying condition;
  5. Alcohol or substance use disorder other than nicotine;
  6. History of epilepsy or recurrent seizures;
  7. Hypersensitivity to cannabinoids or any of the excipients of the study medication;
  8. Clinically relevant cardiac dysfunction within the last 12 months or had a cardiac disorder that, in the opinion of the investigator would put the subject at risk of a clinically relevant arrhythmia or myocardial infarction;
  9. Impaired renal function i.e., serum creatinine clearance lower than 50 ml/min;
  10. Significantly impaired hepatic function, at visit 1, in the investigator's opinion and/or had liver function tests of equal to or greater than three times the upper limit of normal;
  11. Pregnancy or breastfeeding;
  12. Men with history of fertility problems and who plan to conceive at any time in the future;
  13. Any participant who plans to conceive either at screening or while enrolled in the study;
  14. Inability (or unwillingness) of women of childbearing potential and men to use a medically acceptable form of contraception throughout the study duration;
  15. Inability to use a medically acceptable form of contraception throughout the study duration; m) any other significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, may influence the result of the study, or the subject's ability to participate in the study;
  16. Intention to travel internationally, or to donate blood during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05092191


Contacts
Layout table for location contacts
Contact: Pierre Duquette 514 890 8000 ext 0831 pierre.duquette.med@ssss.gouv.qc.ca
Contact: Amel Zertal 514 890 8000 ext 30883 amel.zertal.chum@ssss.gouv.qc.ca

Locations
Layout table for location information
Canada, Quebec
CRCHUM Recruiting
Montreal, Quebec, Canada, H2X 0A9
Contact: Amel, Zertal (Project Manager)    15148908000 ext 30883    amel.zertal.chum@ssss.gouv.qc.ca   
Contact: Dr Pierre, Duquette (PI)    15148908000 ext 0831    pierre.duquette.med@ssss.gouv.qc.ca   
Sponsors and Collaborators
Centre hospitalier de l'Université de Montréal (CHUM)
Canadian Institutes of Health Research (CIHR)
Multiple Sclerosis Society of Canada
Investigators
Layout table for investigator information
Principal Investigator: Pierre Duquette, MD Centre hospitalier de l'Université de Montréal (CHUM)
Layout table for additonal information
Responsible Party: Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov Identifier: NCT05092191    
Other Study ID Numbers: 2021-9017
431518 ( Other Grant/Funding Number: Canadian Institutes of Health Research )
AA1 ( Other Grant/Funding Number: Multiple Sclerosis Society of Canada )
First Posted: October 25, 2021    Key Record Dates
Last Update Posted: December 1, 2022
Last Verified: November 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases